Treatment of Livedoid Vasculopathy with Antiphospholipid Syndrome After Low-Molecular-Weight Heparin

Clinical Scenario

This protocol addresses livedoid vasculopathy in patients with antiphospholipid antibodies present, confirming antiphospholipid syndrome. In this population, not all anticoagulant options are suitable — specific class selection is essential to avoid increasing the risk of recurring thrombotic events.

Prior Treatment — Target Not Reached

Low-molecular-weight heparin was the first-line intervention in this setting. This protocol applies when the expected pain relief within 2–4 days of initiating low-molecular-weight heparin has not been achieved, and escalation is required.

Next-Line Approach

The escalated regimen transitions to oral anticoagulation with a coumarin-type agent — carefully titrated, with defined monitoring targets and specific additional considerations depending on the patient's coagulation protein profile.

Treatment Goal

Anticoagulation intensity is maintained within a defined therapeutic range, tracked by INR monitoring.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/ddg.14520

If antiphospholipid antibodies are present, DOAC should not be used since treatment with rivaroxaban in patients with antiphospholipid syndrome has been shown to increase the risk of recurring thrombotic events.

Phenprocoumon (such as Marcumar) and warfarin (such as Coumadin) inhibit vitamin K dependent coagulation factors as well as the anticoagulant proteins C and S which are relevant for micro-circulation.

The therapeutic range is between INR 2.5 and 3.5.

In cases of protein C or protein S deficiency, treatment initiation must be complemented with additional heparin.

Since there are new, safer alternatives, and due to the reduction of protein C and S concentrations, coumarin derivatives should now be limited to exceptional cases such as antiphospholipid syndrome (off label).

View source ↗